Clinical trials: Pancreatic Adenocarcinoma Resectable
Pancreas Cancer, Adenocarcinoma
Neoadjuvant Treatment of Resectable or Locally Advanced Borderline Pancreatic Adenocarcinoma: Reproducibility of Tumor Measurement in CT VS MRI
Despite important therapeutic advances, pancreatic adenocarcinoma remains one of the cancers with a high mortality rate (4th leading cause of cancer death in the US in 2021), poor prognosis (5-year overall survival rate of 10%)…
- Trial name
- ReMeTTI (NCT05511116)
- Where
- France
- Volunteers
- 48 people
- Sponsor
- Fondation Hôpital Saint-Joseph
Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas
Stereotactic Radiosurgery and Metformin in Patients With Borderline-Resectable or Locally-Advanced Pancreatic Cancer
This pilot clinical trial studies stereotactic radiosurgery and metformin hydrochloride in treating patients with pancreatic cancer that may be removed (borderline-resectable) or not removed by surgery.
- Conditions
- Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage I-III Pancreatic Cancer
- Trial name
- NCT02153450
- Testing
- metformin hydrochloride, stereotactic radiosurgery
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Case Comprehensive Cancer Center
Pancreatic Adenocarcinoma
Alternative Neoadjuvant Chemotherapy in Resectable and Borderline Resectable Pancreatic Cancer
Using alternative neoadjuvant gemcitabine-nab-paclitaxel and nal-IRI with 5-Fluorouracil (5FU) and folinic acid (Leucovorin) regimens of localized cancer, we hope to ensure exposure of the cancer to a broader array of potentially…
- Trial name
- NCT03703063
- Testing
- Gemcitabine, nab paclitaxel, Onivyde
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Benaroya Research Institute
Pancreas Cancer, Pancreatic Cancer
Study To Establish Maximum Tolerated Dose (MTD) of Cyberknife in Patients With Un-Resectable Pancreas Cancer (TL002)
This study is looking at determining the maximum safe dose of CyberKnife when given with chemotherapy for unresectable adenocarcinoma of the pancreas.
- Conditions
- Pancreas Cancer, Pancreatic Cancer, Adenocarcinoma of the Pancreas, Pancreas Adenocarcinoma
- Trial name
- NCT02707328
- Testing
- Gemcitabine, nab-paclitaxel, CyberKnife
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- The Cooper Health System
Pancreatic Cancer
Gemcitabine With or Without WX-671 in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed By Surgery
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00499265
- Testing
- gemcitabine hydrochloride, Serine Proteinase Inhibitor WX-671
- Where
- 39 sites in Germany, Hungary and 4 more
- Volunteers
- 95 people
- Sponsor
- Heidelberg Pharma AG
Pancreatic Adenocarcinoma, Stage IIA Pancreatic Cancer
Gemcitabine Hydrochloride, and Radiation Therapy in Patients With Borderline Resectable Pancreatic Cancer
This phase II trial studies how well combination chemotherapy, gemcitabine hydrochloride, and radiation therapy before surgery works in treating patients with pancreatic cancer that has not spread to other places in the body and…
- Conditions
- Pancreatic Adenocarcinoma, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage III Pancreatic Cancer
- Trial name
- NCT01897454
- Testing
- Fluorouracil, Gemcitabine Hydrochloride, Intensity-Modulated Radiation Therapy
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Albert Einstein College of Medicine
Pancreatic Cancer
Preoperative Chemotherapy (Gemcitabine and Erlotinib) With or Without Radiation Therapy
Primary Objective: To assess margin positive resection rate (R1 resection rate; defined as "tumor within 2 mm of surgical margin on final pathology report") in patients treated with preoperative chemotherapy (gemcitabine and…
- Trial name
- NCT00766636
- Testing
- Gemcitabine, Radiation Therapy, Erlotinib
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- M.D. Anderson Cancer Center
Adenocarcinoma of the Pancreas, Adenocarcinoma of the Duodenum
Efficacy and Safety of TPIAT for Resectable Adenocarcinoma of the Pancreas Region at High Risk of Postoperative Fistula
Curative management of locally resectable invasive adenocarcinomas located in the cephalic region of the pancreas (pancreas, duodenum and ampulla of Vater) requires a pancreaticoduodenectomy followed by adjuvant chemotherapy.
- Conditions
- Adenocarcinoma of the Pancreas, Adenocarcinoma of the Duodenum, Ampullary Adenocarcinoma
- Trial name
- TPIAT-01 (NCT05116072)
- Testing
- total pancreatectomy, intraportal islet autotransplantation
- Where
- France
- Volunteers
- 36 people
- Sponsor
- University Hospital, Lille
Pancreatic Adenocarcinoma
Efficacy and Safety of a Neoadjuvant Treatment in Pancreatic Cancer
This is a Phase II open study, not randomized with a neoadjuvant therapy,combination of Gemcitabine (1,000 mg/m2/week) with Erlotinib (100mg/day) (3 cycles of 4 weeks), followed by gemcitabine (300 mg/m2/week) combined with…
- Trial name
- GEMCAD1003 (NCT01389440)
- Testing
- Gemcitabine and Erlotinib
- Where
- 10 sites in Spain
- Volunteers
- 24 people
- Sponsor
- Grupo Espanol Multidisciplinario del Cancer Digestivo
Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix
EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer
This clinical trial is studying the amount of EF5 and motexafin lutetium present in tumor cells and/or normal tissues of patients with abdominal (such as ovarian, colon, or stomach cancer) or non-small cell lung cancer.
- Conditions
- Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix, Fallopian Tube Cancer, Gastrointestinal Stromal Tumor
- Trial name
- NCT00087191
- Testing
- EF5, motexafin lutetium, pharmacological study
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Pancreatic Adenocarcinoma Non-resectable, Pancreatic Adenocarcinoma Metastatic
Open-Label Phase 2 Efficacy Trial of Cancer Macrobeads in Patients With Treatment-Resistant Pancreatic/Colorectal Cancer
This is a clinical research study of an investigational (FDA BB-IND 10091) treatment for patients with pancreatic cancer (all stages) and advanced colorectal cancer that no longer responds to standard therapies.
- Conditions
- Pancreatic Adenocarcinoma Non-resectable, Pancreatic Adenocarcinoma Metastatic, Colorectal Cancer Metastatic
- Trial name
- Macrobead (NCT01053013)
- Testing
- RENCA macrobeads
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- The Rogosin Institute
Borderline Resectable Pancreatic Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma
Nivolumab in Combination With Chemotherapy Pre-Surgery in Treating Patients With Borderline Resectable Pancreatic Cancer
This pilot and feasibility study studies how well nivolumab and combination chemotherapy work before surgery in treating patients with pancreatic cancer that could possibly be removed by surgery.
- Trial name
- NCT03970252
- Testing
- Fluorouracil, Irinotecan, Irinotecan Hydrochloride
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Pancreatic Adenocarcinoma, Pancreatic Cancer
Eus-guided Cryothermal Ablation in Stage III Pancreatic Adenocarcinoma
Pancreatic cancer represents the 11th most commonly diagnosed cancer in men and 9th in women, being the third leading cause of cancer-related death in the Western countries.
- Conditions
- Pancreatic Adenocarcinoma, Pancreatic Cancer, Pancreas Neoplasm
- Trial name
- NCT03649035
- Testing
- HTP treatment
- Where
- Italy
- Sponsor
- Istituto Clinico Humanitas
Pancreatic Adenocarcinoma
A Study of the Safety and Activity of Liposomal Irinotecan in Combination With the 5-FU and Oxaliplatin in the Preoperative Treatment of Pancreatic Adenocarcinoma
This is a phase II, single arm, non-randomized, open label study of liposomal irinotecan with FOLFOX in the neoadjuvant setting in patients with resectable or borderline resectable, previously untreated pancreatic adenocarcinoma.
- Trial name
- NCT03483038
- Testing
- Liposomal Irinotecan, FOLFOX regimen
- Where
- 4 sites in United States
- Volunteers
- 45 people
- Sponsor
- University of Florida
Adenocarcinoma of the Pancreas, Stage IA Pancreatic Cancer
Perioperative Therapy for Resectable Pancreatic Cancer
This phase II trial studies how well giving combination chemotherapy together with intensity-modulated radiation therapy (IMRT) and surgery works in treating patients with localized pancreatic cancer that can be removed by…
- Conditions
- Adenocarcinoma of the Pancreas, Stage IA Pancreatic Cancer, Stage IB Pancreatic Cancer, Stage IIA Pancreatic Cancer
- Trial name
- NCT00609336
- Testing
- gemcitabine hydrochloride, docetaxel, capecitabine
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- University of Washington
Resectable Pancreatic Cancer
Borderline Pancreas Study: FOLFIRINOX +SBRT
Primary Objective: To determine the rate of downstaging to resectability in patients with borderline resectable pancreatic cancer receiving FOLFIRINOX and SBRT as preoperative therapy. Secondary Objective(s): 1.
- Trial name
- GCC 1324 (NCT01992705)
- Testing
- Chemotherapy(FOLFIRINOX) + SBRT prior to surgery if applicable, -Oxaliplatin 85 mg/m2 IV on Day 1, -Irinotecan 180 mg/m2 IV on Day 1
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of Maryland, Baltimore
Pancreatic Adenocarcinoma Non-resectable
EUS-RFA for Unresectable Pancreatic Ductal Adenocarcinoma
the study evaluate the efficacy and safety of EUS-RFA using Habib EUS-RFA catheter with a prospective randomised trial in patients with inoperable PDAC.
- Trial name
- NCT03772756
- Testing
- Endoscopic ultrasound guided radiofrequency ablation, chemoradiotherapy
- Where
- 2 sites in China
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- First People's Hospital of Hangzhou
Pancreatic Adenocarcinoma Non-resectable
PEGPH20 Plus Gemcitabine With Radiotherapy in Patients With Localized, Unresectable Pancreatic Cancer
This is a single arm phase II trial assessing the potential activity of combination PEGPH20 plus Gemcitabine with radiotherapy in ten patients with localized, unresectable pancreatic adenocarcinoma.
- Trial name
- HALO-IST (NCT02910882)
- Testing
- PEGylated Recombinant Human Hyaluronidase (PEGPH20), Gemcitabine, Radiation
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Scripps Health
Ovarian Cancer, Pancreas Cancer
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Study QXL138AM-001 is a Phase 1a/1b study to investigate the safety, pharmacokinetics, and preliminary activity of QXL138AM in subjects with locally advanced un-resectable and/or metastatic solid tumors and multiple myeloma.
- Conditions
- Ovarian Cancer, Pancreas Cancer, Urothelial Carcinoma, Renal Cell Carcinoma
- Trial name
- NCT06582017
- Testing
- QXL138AM Injection every 2 weeks by IV Infusion
- Where
- 11 sites in United States
- Volunteers
- 100 people
- Sponsor
- Nammi Therapeutics Inc
Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas
Chemoradiation and Radiosurgery Boost in Treating Patients With Locally Advance Pancreatic Cancer That May or May Not be Removed by Surgery
This phase I trial studies the side effects and best dose of radiosurgery boost following chemoradiation in treating patients with locally advanced pancreatic cancer that may or may not be removed by surgery.
- Conditions
- Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Stage IIB Pancreatic Cancer, Stage III Pancreatic Cancer
- Trial name
- NCT01739439
- Testing
- gemcitabine hydrochloride, hyperfractionated radiation therapy, intensity-modulated radiation therapy
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Fox Chase Cancer Center